Multi-epitope vaccine against SARS-CoV-2 targeting the spike RBD: an immunoinformatics approach

IF 2.4 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Future Science OA Pub Date : 2024-01-01 DOI:10.2144/fsoa-2023-0081

Y. Pahlavan, Omid Yeganeh, Vahid Asghariazar, Chiman Karami

引用次数: 0

Abstract

Aim: We designed a SARS-CoV-2 epitope vaccine based on the receptor-binding domain (RBD) in virus spike protein. Methods: RT-PCR performed on nasopharyngeal swab COVID-19 patients. After registering RBD region in the GenBank, physicochemical parameters, secondary structure, homology modeling, 3D structure of RBD region and antigenicity were determined using ProtParam ExPASy, PSIPRED, MolProbity, IEDB and Vaxijen online tools, respectively. Results: B and T cell epitopes were predicted in terms of non-allergenicity and antigenicity. MolProbity analysis provided a qualitative model for RBD. The homology model showed that most of the residues are in optimal district of energy. Conclusion: High immunogenicity score of epitopes indicates promising candidates for the development of multi-epitope vaccines. It may help to develop an effective vaccine.

查看原文本刊更多论文

针对尖峰 RBD 的 SARS-CoV-2 多表位疫苗：一种免疫信息学方法

目的：我们根据病毒尖峰蛋白中的受体结合域（RBD）设计了一种 SARS-CoV-2 表位疫苗。方法：对鼻咽拭子 COVID 进行 RT-PCR 检测：对 COVID-19 患者的鼻咽拭子进行 RT-PCR 扩增。在 GenBank 中登记 RBD 区域后，分别使用 ProtParam ExPASy、PSIPRED、MolProbity、IEDB 和 Vaxijen 在线工具测定 RBD 区域的理化参数、二级结构、同源建模、三维结构和抗原性。结果预测了 B 细胞和 T 细胞表位的非过敏性和抗原性。MolProbity 分析为 RBD 提供了一个定性模型。同源模型显示，大多数残基都处于最佳能量区。结论表位的高免疫原性得分表明，多表位疫苗的开发很有希望。它可能有助于开发出有效的疫苗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future Science OA MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

5.00

自引率

4.00%

发文量

审稿时长

13 weeks

期刊介绍： Future Science OA is an online, open access, peer-reviewed title from the Future Science Group. The journal covers research and discussion related to advances in biotechnology, medicine and health. The journal embraces the importance of publishing all good-quality research with the potential to further the progress of research in these fields. All original research articles will be considered that are within the journal''s scope, and have been conducted with scientific rigour and research integrity. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis. Submissions of the following article types will be considered: -Research articles -Preliminary communications -Short communications -Methodologies -Trial design articles -Trial results (including early-phase and negative studies) -Reviews -Perspectives -Commentaries